ATRC logo

AtriCure (ATRC) Company Overview

Profile

Full Name:

AtriCure, Inc.

Sector:

Healthcare

Country:

United States

IPO:

August 5, 2005

Indexes:

Not included

Description:

AtriCure, Inc. is a large healthcare system company that specializes in the development, manufacturing, and sale of equipment and systems for physicians working in the field of cardiothoracic surgery in the United States and abroad. The company was founded in 2000 and is based in Mason, Ohio. The company's portfolio includes 3 categories of products: Products for open and minimally invasive ablation include a range of Synergy Isolator clamps for the treatment of persistent atrial fibrillation. The company's products for open ablation include the CryoICE cryoablation system. Products for minimally invasive ablation provide a coagulation system under EPi-Sense control with VisiTrax technology, using monopolar energy for tissue coagulation.

Key Details

Price

$41.39

Annual Revenue

$399.25 M(+20.84% YoY)

Annual EPS

-$0.66(+35.29% YoY)

Beta

1.14

Events Calendar

Earnings

Next earnings date:

Feb 12, 2025

Recent quarterly earnings:

Oct 29, 2024

Recent annual earnings:

Feb 15, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 22, 25 Needham
Buy
Jan 13, 25 Needham
Buy
Dec 9, 24 Canaccord Genuity
Buy
Oct 30, 24 UBS
Buy
Oct 30, 24 Oppenheimer
Outperform
Oct 30, 24 Needham
Buy
Oct 30, 24 JP Morgan
Overweight
Oct 30, 24 Canaccord Genuity
Buy
Jul 31, 24 Stifel
Buy
Jul 31, 24 Piper Sandler
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
ATRC
businesswire.comDecember 23, 2024

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio.

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
ATRC
seekingalpha.comOctober 29, 2024

AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call.

AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
ATRC
zacks.comOctober 29, 2024

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
ATRC
zacks.comOctober 29, 2024

AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago.

AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
ATRC
zacks.comOctober 16, 2024

ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.

AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
ATRC
zacks.comOctober 11, 2024

ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.

AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
ATRC
zacks.comAugust 28, 2024

ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
ATRC
zacks.comAugust 23, 2024

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.

AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
ATRC
seekingalpha.comJuly 31, 2024

AtriCure, Inc. (NASDAQ:ATRC ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
ATRC
zacks.comJuly 30, 2024

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for AtriCure?
  • Does AtriCure pay dividends?
  • What sector is AtriCure in?
  • What industry is AtriCure in?
  • What country is AtriCure based in?
  • When did AtriCure go public?
  • Is AtriCure in the S&P 500?
  • Is AtriCure in the NASDAQ 100?
  • Is AtriCure in the Dow Jones?
  • When was AtriCure's last earnings report?
  • When does AtriCure report earnings?
  • Should I buy AtriCure stock now?

What is the ticker symbol for AtriCure?

The ticker symbol for AtriCure is NASDAQ:ATRC

Does AtriCure pay dividends?

No, AtriCure does not pay dividends

What sector is AtriCure in?

AtriCure is in the Healthcare sector

What industry is AtriCure in?

AtriCure is in the Medical Instruments & Supplies industry

What country is AtriCure based in?

AtriCure is headquartered in United States

When did AtriCure go public?

AtriCure's initial public offering (IPO) was on August 5, 2005

Is AtriCure in the S&P 500?

No, AtriCure is not included in the S&P 500 index

Is AtriCure in the NASDAQ 100?

No, AtriCure is not included in the NASDAQ 100 index

Is AtriCure in the Dow Jones?

No, AtriCure is not included in the Dow Jones index

When was AtriCure's last earnings report?

AtriCure's most recent earnings report was on Oct 29, 2024

When does AtriCure report earnings?

The next expected earnings date for AtriCure is Feb 12, 2025

Should I buy AtriCure stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions